- Conditions
- Breast Cancer
- Interventions
- ctDNA MRD test
- Diagnostic Test
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 53
- States / cities
- Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–137
of 137
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Cancer of the Breast
- Interventions
- VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Thrombocytopenia
- Interventions
- T-TAS 01 HD Assay
- Diagnostic Test
- Lead sponsor
- Hikari Dx, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- San Francisco, California • Denver, Colorado • Baltimore, Maryland + 3 more
- Conditions
- Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
- Interventions
- Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
- Diagnostic Test · Drug · Device
- Lead sponsor
- Cari Health Inc.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Lemon Grove, California
- Conditions
- Metastatic Melanoma, Advanced Melanoma
- Interventions
- Nivolumab, Relatlimab, Ipilimumab, Signatera genome MRD assay
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
- Device
- Lead sponsor
- Abbott Diagnostics Division
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41,862 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Lakeland, Florida • St. Petersburg, Florida • Glenview, Illinois + 4 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma, Colorectal Disorders, Colorectal Dysplasia, Colorectal Cancer Stage I, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Colorectal Neoplasms Malignant, Colorectal Serrated Adenocarcinoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Adenoma With Mild Dysplasia, Colorectal Adenoma With Moderate Dysplasia, Colorectal Adenoma and Carcinoma 1, Colorectal Adenomatous Polyp, Colorectal Adenocarcinoma Metastatic in the Liver
- Interventions
- DENEB
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Monrovia, California • San Diego, California
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Interventions
- NETest
- Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- G6PD, G6PD Deficiency
- Interventions
- G6PD assay
- Diagnostic Test
- Lead sponsor
- Baebies, Inc.
- Industry
- Eligibility
- 35 Weeks to 100 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Raleigh, North Carolina • Cleveland, Ohio
- Conditions
- Plague, Plague, Bubonic, Plague, Pneumonic, Yersinia Pestis Plague, Yersinia Pestis; Bubo, Yersinia Pestis; Pneumonia, Yersinia Sepsis, Yersinia Pestis Infection, Bubo; Yersinia Pestis, Bubonic; Plague, Skin, Pneumonic Plague
- Interventions
- Lateral Flow Assay for Pathogens of the Plague
- Diagnostic Test
- Lead sponsor
- Brimrose Technology Corporation
- Industry
- Eligibility
- 5 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Fetal Sex Determination
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- San Diego, California
- Conditions
- Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
- Procedure · Device · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer Aggressiveness
- Interventions
- Subtraction Normalized Expression of Phagocytes Blood Test
- Diagnostic Test
- Lead sponsor
- Immunis.AI
- Industry
- Eligibility
- 40 Years to 80 Years · Male only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Acquired Immunodeficiency Syndrome
- Interventions
- Investigational BD FACSPresto System, BD FACSCalibur flow cytometer, Sysmex hematology analyzer KX-21
- Device
- Lead sponsor
- Becton, Dickinson and Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • San Jose, California
- Conditions
- Lyme Disease
- Interventions
- PCR based assay, Serology based assay, Tcell based assay
- Diagnostic Test
- Lead sponsor
- Oxford Immunotec
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 60
- States / cities
- Redding, California • New London, Connecticut • Norwalk, Connecticut + 53 more
- Conditions
- Rehumanization Intervention, Control Intervention
- Interventions
- Rehumanized Intervention, Control Intervention, Clinical Interview, Self-Report Measures, Blood Draw
- Other · Diagnostic Test
- Lead sponsor
- Florida State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tallahassee, Florida
- Conditions
- Solid Tumors, Hematologic Cancers
- Interventions
- molecular profiling of tumors, Clinical Germline Analysis
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 18
- States / cities
- Bridgeport, Connecticut • Hartford, Connecticut • Norwalk, Connecticut + 13 more